Edgewise reports mid-stage trial data for heart disease drug, shares fall

Edgewise Therapeutics

16/06/2026 15:01

Update
** Shares of Edgewise Therapeutics EWTX.O fall 10% to $31.71
** Drug developer says its experimental drug, EDG-7500, met the main goal of a mid-stage trial in patients with hypertrophic cardiomyopathy (HCM), a condition in which the heart muscles abnormally thicken 
** In the 12-week study of 53 patients with obstructive and non-obstructive HCM, the drug showed no meaningful reductions in left ventricular ejection fraction, a key measure of heart function, and no patients fell below 50%
** RBC Capital Markets says the efficacy data in non-obstructive HCM may have underwhelmed some investors, but it adds that EDG-7500 appears competitive compared with existing cardiac myosin inhibitors
** Brokerage says the stock's drop "seems overdone"
** Truist says investors may be concerned about enrollment timelines, the potential need for head-to-head trials and delays before phase 3 data
** Co says late-stage trial is planned to begin in Q4 2026
** Including session moves, stock up 35.6% YTD 

 (Reporting by Siddhi Mahatole)
 ((siddhi.mahatole@thomsonreuters.com))